Frank McCormick, Director at BridgeBio Pharma, Inc. (BBIO), sold 100,000 shares at $42.06 ($4.2M) on 2023-12-26, disclosed to the SEC on 2023-12-28.
Scheduled sale ($4.2M) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| BBIO | SELL | 2025-09-08 | $7.9M | — | Filing → |
| BBIO | SELL | 2025-06-26 | $4.4M | — | Filing → |
| BBIO | SELL | 2020-11-17 | $8.6M | — | Filing → |